BR112017010311A2 - 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 - Google Patents

4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Info

Publication number
BR112017010311A2
BR112017010311A2 BR112017010311A BR112017010311A BR112017010311A2 BR 112017010311 A2 BR112017010311 A2 BR 112017010311A2 BR 112017010311 A BR112017010311 A BR 112017010311A BR 112017010311 A BR112017010311 A BR 112017010311A BR 112017010311 A2 BR112017010311 A2 BR 112017010311A2
Authority
BR
Brazil
Prior art keywords
gpr139
benzotriazines
modulators
dihydro
oxo
Prior art date
Application number
BR112017010311A
Other languages
English (en)
Inventor
Lam Betty
Monenschein Holger
Reichard Holly
Hitchcock Stephen
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112017010311A2 publication Critical patent/BR112017010311A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Abstract

a presente invenção refere-se a um método para o tratamento de uma doença, distúrbio ou condição associada a gpr139 usando compostos de fórmula (1), que são agonistas de gpr139, certos compostos abrangidos pela fórmula (1), composições farmacêuticas dos mesmos, processos para a preparação dos compostos e seus intermediários.
BR112017010311A 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 BR112017010311A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25
PCT/US2015/061607 WO2016081736A1 (en) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139

Publications (1)

Publication Number Publication Date
BR112017010311A2 true BR112017010311A2 (pt) 2017-12-26

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010311A BR112017010311A2 (pt) 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (pt)
EP (2) EP3536324B1 (pt)
JP (2) JP6637501B2 (pt)
KR (1) KR102582021B1 (pt)
CN (2) CN107108531B (pt)
AU (1) AU2015349866B2 (pt)
BR (1) BR112017010311A2 (pt)
CA (1) CA2968242C (pt)
CL (1) CL2017001292A1 (pt)
CO (1) CO2017005959A2 (pt)
CR (1) CR20170275A (pt)
CY (2) CY1122613T1 (pt)
DK (2) DK3221298T3 (pt)
DO (1) DOP2017000120A (pt)
EA (1) EA033728B1 (pt)
EC (1) ECSP17038999A (pt)
ES (2) ES2734735T3 (pt)
GE (1) GEP20196961B (pt)
HR (2) HRP20212009T1 (pt)
HU (2) HUE057451T2 (pt)
IL (1) IL252311B (pt)
JO (1) JO3719B1 (pt)
LT (2) LT3221298T (pt)
MA (1) MA40993B1 (pt)
MD (1) MD3221298T2 (pt)
MX (1) MX2017006448A (pt)
MY (1) MY187423A (pt)
NZ (1) NZ732208A (pt)
PE (1) PE20170899A1 (pt)
PH (1) PH12017500920B1 (pt)
PL (2) PL3536324T3 (pt)
PT (2) PT3536324T (pt)
RS (2) RS62563B1 (pt)
SG (1) SG11201704002UA (pt)
SI (2) SI3221298T1 (pt)
TN (1) TN2017000196A1 (pt)
TW (1) TWI684590B (pt)
UA (1) UA120375C2 (pt)
UY (1) UY36406A (pt)
WO (1) WO2016081736A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
CA3121108A1 (en) * 2018-10-16 2020-04-23 The Scripps Research Institute Methods related to opioid therapeutics
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
AR119971A1 (es) 2019-09-16 2022-01-26 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
WO2021224680A1 (en) * 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
TW202227087A (zh) 2020-09-21 2022-07-16 日商武田藥品工業股份有限公司 精神分裂症之治療
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
DE3752141T2 (de) 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
DE3850742T2 (de) * 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004261283B2 (en) 2003-07-31 2008-05-01 Irm, Llc Bicyclic compounds and compositions as PDF inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
JP2010521513A (ja) * 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー アザ−ピリドピリミジノン誘導体
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2014152917A2 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
HUE044145T2 (hu) 2019-09-30
EP3536324A1 (en) 2019-09-11
US11173161B2 (en) 2021-11-16
EP3221298A1 (en) 2017-09-27
US20170095480A1 (en) 2017-04-06
CO2017005959A2 (es) 2017-10-20
GEP20196961B (en) 2019-03-25
HRP20212009T1 (hr) 2022-04-01
JP6637501B2 (ja) 2020-01-29
ES2734735T3 (es) 2019-12-11
US10159677B2 (en) 2018-12-25
KR20170084324A (ko) 2017-07-19
EP3536324B1 (en) 2021-10-06
PL3536324T3 (pl) 2022-02-07
CN107108531B (zh) 2020-10-20
SI3221298T1 (sl) 2019-10-30
LT3221298T (lt) 2019-08-12
DOP2017000120A (es) 2017-06-15
PH12017500920A1 (en) 2017-11-20
CN107108531A (zh) 2017-08-29
US20190070187A1 (en) 2019-03-07
JP2017535559A (ja) 2017-11-30
US20170348319A1 (en) 2017-12-07
DK3221298T3 (da) 2019-06-24
EA201791096A1 (ru) 2017-11-30
PH12017500920B1 (en) 2017-11-20
HRP20191003T1 (hr) 2019-08-23
US9770450B2 (en) 2017-09-26
EP3221298B1 (en) 2019-04-03
CL2017001292A1 (es) 2018-02-16
AU2015349866B2 (en) 2020-12-03
CA2968242A1 (en) 2016-05-26
IL252311A0 (en) 2017-07-31
LT3536324T (lt) 2021-12-10
UA120375C2 (uk) 2019-11-25
US20200129518A1 (en) 2020-04-30
MX2017006448A (es) 2017-09-12
IL252311B (en) 2020-07-30
KR102582021B1 (ko) 2023-09-22
CY1124929T1 (el) 2023-01-05
UY36406A (es) 2016-06-30
WO2016081736A1 (en) 2016-05-26
MA40993B1 (fr) 2019-07-31
TWI684590B (zh) 2020-02-11
US9556130B2 (en) 2017-01-31
HUE057451T2 (hu) 2022-05-28
CA2968242C (en) 2022-11-08
DK3536324T3 (da) 2021-10-25
PT3221298T (pt) 2019-06-28
EA033728B1 (ru) 2019-11-20
CN112062730B (zh) 2023-09-29
JO3719B1 (ar) 2021-01-31
TW201625566A (zh) 2016-07-16
US20160145218A1 (en) 2016-05-26
ES2897545T3 (es) 2022-03-01
PT3536324T (pt) 2021-11-10
CY1122613T1 (el) 2021-05-05
JP6918088B2 (ja) 2021-08-11
US10561662B2 (en) 2020-02-18
CR20170275A (es) 2017-10-30
JP2020063285A (ja) 2020-04-23
SI3536324T1 (sl) 2021-12-31
PL3221298T3 (pl) 2019-10-31
NZ732208A (en) 2023-02-24
MD3221298T2 (ro) 2019-10-31
SG11201704002UA (en) 2017-06-29
RS59078B1 (sr) 2019-09-30
AU2015349866A1 (en) 2017-06-15
MA40993A (fr) 2017-09-27
PE20170899A1 (es) 2017-07-12
MY187423A (en) 2021-09-22
TN2017000196A1 (en) 2018-10-19
RS62563B1 (sr) 2021-12-31
CN112062730A (zh) 2020-12-11
ECSP17038999A (es) 2017-10-31

Similar Documents

Publication Publication Date Title
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
EA201691134A1 (ru) Новые ингибиторы глутаминазы
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112016028255A2 (pt) agentes imunorreguladores
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
EA201790570A1 (ru) Модуляторы р2х7
BR112016021535A8 (pt) kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112017013194A2 (pt) síntese total de trioxacarcina dc-45-a2 e preparação de análogos de trioxacarcina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]